上海
分享至
科笛-B1月31日在港交所公告，集团的CU-40102（外用非那雄胺喷雾剂）新药上市申请（NDA）获得中国国家药品监督管理局受理。CU-40102的适应症为治疗雄激素性脱发。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
